U.S. markets open in 7 hours 23 minutes

ANI Pharmaceuticals, Inc. (ANIP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
29.57-0.48 (-1.60%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
Previous Close30.05
Open30.09
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range29.37 - 30.36
52 Week Range23.55 - 52.22
Volume30,349
Avg. Volume64,188
Market Cap365.438M
Beta (5Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-1.98
Earnings DateMar 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
48% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline
    Zacks

    Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline

    ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Business Wire

    ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI’s Senior Vice President, Generics, and an aggregate of 33,758 shares to Christopher Mutz, ANI’s Chief Commercial Officer & Head of Rare Disease, effective February 15, 2021.

  • Business Wire

    ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth

    ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the addition of three key pharmaceutical executives: Christopher K. Mutz as Chief Commercial Officer and Head of Rare Diseases; Ori Gutwerg as Senior Vice President of Generics; and Davinder Singh as General Manager, Canadian Operations.